Cargando…

Prediction factors of tolvaptan effectiveness in patients with refractory ascites complicated with hepatocellular carcinoma

OBJECTIVE: Tolvaptan (TVP) is an effective treatment for patients with cirrhotic ascites; however, studies have indicated that a sufficient effect is difficult to obtain in patients with hepatocellular carcinoma (HCC). This study evaluates the efficacy of TVP in patients with HCC with refractory asc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imai, Michitaka, Ishikawa, Toru, Kojima, Yuichi, Azumi, Motoi, Nozawa, Yujiro, Sano, Tomoe, Iwanaga, Akito, Honma, Terasu, Yoshida, Toshiaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams And Wilkins 2020
Materias:	Original Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734621/ https://www.ncbi.nlm.nih.gov/pubmed/33196517 http://dx.doi.org/10.1097/MEG.0000000000001985

Ejemplares similares

Comparison of the efficacy of self-expandable metallic stents in colorectal obstructions caused by extracolonic malignancy and colorectal cancer
por: Sano, Tomoe, et al.
Publicado: (2021)

Changes in the Body Composition and Nutritional Status after Long-term Rifaximin Therapy for Hyperammonemia in Japanese Patients with Hepatic Encephalopathy
por: Ishikawa, Toru, et al.
Publicado: (2020)

Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia
por: Ishikawa, Toru, et al.
Publicado: (2019)

Cone beam versus conventional computed tomography angiography volume measurement in partial splenic embolization
por: Ishikawa, Toru, et al.
Publicado: (2019)

Clinical Usefulness of Transjugular Liver Biopsy in Patients With Hematological Diseases With Liver Dysfunction
por: Ishikawa, Toru, et al.
Publicado: (2021)

Evaluation of the branched-chain amino acid-to-tyrosine ratio prior to treatment as a prognostic predictor in patients with liver cirrhosis
por: Ishikawa, Toru, et al.
Publicado: (2017)

Successful Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin Retreatment for a Chronic Hepatitis C Genotype 2a Patient Who Relapsed after Sofosbuvir Plus Ribavirin Treatment
por: Ishikawa, Toru, et al.
Publicado: (2018)

Analysis of predictors after partial splenic embolization for thrombocytopenia with liver cirrhosis
por: Ishikawa, Toru, et al.
Publicado: (2022)

Eosinophilic esophagitis in Japanese patients: A mild and slow-progressing disorder
por: Sato, Hiroki, et al.
Publicado: (2018)

Hemorrhagic Gastric Metastasis from Hepatocellular Carcinoma Successfully Treated Using Coil Embolization of the Left Gastric Artery
por: Imai, Michitaka, et al.
Publicado: (2019)

Improved survival with double platinum therapy transcatheter arterial infusion using cisplatin and transcatheter arterial chemoembolization using miriplatin for BCLC-B hepatocellular carcinoma
por: Ishikawa, Toru, et al.
Publicado: (2016)

Clinical efficacy of the highly sensitive hepatitis C virus RNA quantitative assay in patients with relapse following interferon-based therapy with second-generation direct-acting antivirals
por: ISHIKAWA, TORU, et al.
Publicado: (2016)

Telaprevir-based triple therapy following partial splenic arterial embolization for chronic hepatitis C with thrombocytopenia can reduce carcinogenesis and improve hepatic function reserve
por: ISHIKAWA, TORU, et al.
Publicado: (2015)

Risk factors for difficult endoscopic hemostasis for colonic diverticular bleeding and efficacy and safety of transcatheter arterial embolization
por: Sano, Tomoe, et al.
Publicado: (2023)

Ascending Colon Varices Due to Left-sided Portal Hypertension
por: Ishikawa, Toru, et al.
Publicado: (2021)

Tolvaptan for the Treatment of Refractory Ascites
por: Kurosaki, Masayuki, et al.
Publicado: (2016)

Cases with Refractory Ascites and a Delayed Response to Tolvaptan
por: Hagiwara, Satoru, et al.
Publicado: (2016)

Effects of body composition and liver function after long-term pemafibrate treatment on dyslipidemia-associated non-alcoholic fatty liver disease
por: Ishikawa, Toru, et al.
Publicado: (2023)

Predictive Factor of Local Recurrence after Balloon-Occluded TACE with Miriplatin (MPT) in Hepatocellular Carcinoma
por: Ishikawa, Toru, et al.
Publicado: (2014)

Comparison of Ablation Volume Between Emprint(®) and Mimapro(®) Systems for Hepatocellular Carcinoma –A Preliminary Study
por: Ishikawa, Toru, et al.
Publicado: (2023)

Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan
por: Iwasa, Motoh, et al.
Publicado: (2019)

Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites
por: Goto, Atsushi, et al.
Publicado: (2014)

Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites
por: Arase, Yoshitaka, et al.
Publicado: (2018)

Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites
por: Hosui, Atsushi, et al.
Publicado: (2021)

Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites
por: Hirooka, Masashi, et al.
Publicado: (2022)

Impact of continued administration of tolvaptan on cirrhotic patients with ascites
por: Kogiso, Tomomi, et al.
Publicado: (2018)

Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan
por: Adachi, Takuya, et al.
Publicado: (2021)

The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan
por: Kogiso, Tomomi, et al.
Publicado: (2017)

First reports of clinical effects of transjugular intrahepatic portosystemic shunt in four patients with cirrhotic ascites refractory to tolvaptan
por: Tsuruya, Kota, et al.
Publicado: (2023)

Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia
por: Wang, Shuzhen, et al.
Publicado: (2018)

Efficacy and safety of tolvaptan for refractory fluid collection and edema in the terminal cancer patients
por: Tsuzuki, Norimasa, et al.
Publicado: (2023)

Efficacy and safety of tolvaptan in patients with malignant ascites: a phase 2, multicenter, open-label, dose-escalation study
por: Kudo, Toshihiro, et al.
Publicado: (2020)

Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study
por: Shiba, Shunsuke, et al.
Publicado: (2020)

Long-Term Tolvaptan Treatment in Refractory Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2019)

Risk and protective factors of acute kidney injury in decompensated cirrhotic patients with ascites on tolvaptan
por: Kogiso, Tomomi, et al.
Publicado: (2021)

Ascites, refractory ascites and hyponatremia in cirrhosis
por: Fortune, Brett, et al.
Publicado: (2017)

Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia
por: Hayashi, Manabu, et al.
Publicado: (2018)

Therapy with the Combination of Tolvaptan and Furosemide for Refractory Edema in Nephrotic Syndrome
por: Meena, Jitendra, et al.
Publicado: (2020)

Refractory Chylous Ascites
por: Soto, Rodrigo, et al.
Publicado: (2008)

Management of refractory ascites
por: Wong, Florence
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v95biq94ker9fgi5rlt8gau59g